Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials by Heinz Gisslinger

Get full text

Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation? by Klaus Geissler, Eva Jäger, Agnes Barna, Thamer Sliwa, Paul Knöbl, Ilse Schwarzinger, Heinz Gisslinger, Peter Valent

Get full text

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome by Lina Z. Rüsing, Nicolas Kozakowski, Georg Jeryczynski, Lea Vospernik, Julia Riedl, Thomas Reiter, Heinz Gisslinger, Hermine Agis, Maria-Theresa Krauth

Get full text

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.... by Jürgen Thiele, Attilio Orazi, Hans Michael Kvasnicka, Vito Franco, Emanuela Boveri, Umberto Gianelli, Heinz Gisslinger, Francesco Passamonti, Ayalew Tefferi, Tiziano Barbui

Get full text

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma by Heinz Ludwig, Zdenek Adam, Elena Tóthová, Roman Hajek, Boris Labar, Miklós Egyed, Ivan Spicka, Heinz Gisslinger, Johannes Drach, Ingrid Kuhn, Axel Hinke, Niklas Zojer

Get full text

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in pat... by Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, Joaquin Martinez Lopez

Get full text

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family by Kun Liu, Robert Kralovics, Zbigniew Rudzki, Barbara Grabowska, Andreas S. Buser, Damla Olcaydu, Heinz Gisslinger, Ralph Tiedt, Patricia Frank, Krzysztof Okoñ, Anthonie P.C. van der Maas, Radek C. Skoda

Get full text

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach by Alessandra Carobbio, Alessandro Maria Vannucchi, Elisa Rumi, Valerio De Stefano, Alessandro Rambaldi, Giuseppe Carli, Maria Luigia Randi, Heinz Gisslinger, Francesco Passamonti, Juergen Thiele, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui

Get full text

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis by Alessandro M. Vannucchi, Peter A. W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger

Get full text

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Get full text

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis by Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès

Get full text

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group

Get full text

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to <100 × 10/L) at baseline: the final analysis of EXPAND by Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger

Get full text

The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies by Alexander Gaiger, Simone Lubowitzki, Katharina Krammer, Elisabeth L. Zeilinger, Andras Acel, Olivera Cenic, Andrea Schrott, Matthias Unseld, Anahita Paula Rassoulian, Cathrin Skrabs, Peter Valent, Heinz Gisslinger, Christine Marosi, Matthias Preusser, Gerald Prager, Gabriela Kornek, Robert Pirker, Günther G. Steger, Rupert Bartsch, Markus Raderer, Ingrid Simonitsch‐Klupp, Renate Thalhammer, Christoph Zielinski, Ulrich Jäger

Get full text

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies by Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F. DiPersio, Mari McQuitty, John V. Catalano, Deborah S. Hunter, Laurent Knoops, Michael Deininger, Francisco Cervantes, Carole Miller, Alessandro M. Vannucchi, Richard T. Silver, Tiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F. Winton, Estella Mendeson, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Victor Sandor, Hagop M. Kantarjian, Claire Harrison

Get full text